DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Abbokinase (Urokinase) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Anticoagulants and agents that alter platelet function (such as aspirin, other non-steroidal anti-inflammatory agents, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of serious bleeding.

Administration of Abbokinase® prior to, during, or after other thrombolytic agents may increase the risk of serious bleeding.

Because concomitant use of Abbokinase® with agents that alter coagulation, inhibit platelet function, or are thrombolytic may further increase the potential for bleeding complications, careful monitoring for bleeding is recommended.

The interaction of Abbokinase® with other drugs has not been studied and is not known.

CONTRAINDICATIONS

The use of Abbokinase® is contraindicated in patients with a history of hypersensitivity to the product (see WARNINGS and ADVERSE REACTIONS).

Because thrombolytic therapy increases the risk of bleeding, Abbokinase® is contraindicated in the situations listed below (see WARNINGS).

  • Active internal bleeding
  • Recent (e.g., within two months) cerebrovascular accident
  • Recent (e.g., within two months) intracranial or intraspinal surgery
  • Recent trauma including cardiopulmonary resuscitation
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Known bleeding diatheses
  • Severe uncontrolled arterial hypertension

REFERENCES

  1. Sato S, et al. Elevated Urokinase-Type Plasminogen Activator Plasma Levels Are Associated With Deterioration of Liver Function But Not With Hepatocellular Carcinoma. J Gastroenterology. 1994; 29: 745-750.
  2. Bell WR. Thrombolytic Therapy: A Comparison Between Urokinase and Streptokinase. Sem Thromb Hemost. 1975; 2:1-13.
  3. Sasahara AA, Hyers TM, Cole CM, et al. The Urokinase Pulmonary Embolism Trial. Circulation. 1973; 47 (suppl. 2): 1-108.
  4. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of Duration of Symptoms With Response to Thrombolytic Therapy in Pulmonary Embolism. Am J Cardiol. 1997; 80:184-188.
  5. Urokinase Pulmonary Embolism Trial Study Group: Urokinase-Streptokinase Embolism Trial. JAMA. 1974; 229:1606-1613.
  6. Sasahara AA, Bell WR, Simon TL, et al. The Phase II Urokinase-Streptokinase Pulmonary Embolism Trial. Thrombos Diathes Haemorrh (Stuttg). 1975; 33:464-476.

©Abbott 2002

ABBOTT LABORATORIES, NORTH CHICAGO, IL 60064, USA

Reference 58-6978-R4-Rev. October, 2002

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014